Format

Send to

Choose Destination
Dement Geriatr Cogn Disord. 2013;35(1-2):23-33. doi: 10.1159/000345989. Epub 2013 Jan 9.

Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine.

Author information

1
Fundació ACE - Barcelona Alzheimer Treatment and Research Centre, Barcelona, Spain.

Abstract

BACKGROUND AND AIMS:

Poor adherence to anti-dementia drugs is common among patients with Alzheimer's disease. This study evaluated whether caregivers were more satisfied with, and patients more adherent to, transdermal rivastigmine than oral rivastigmine.

METHODS:

Neurologists, psychiatrists and geriatricians collected sociodemographic and clinical data from 1,078 patients and administered the Treatment Satisfaction with Medicines (SATMED-Q) and the Morisky-Green questionnaires to their caregivers at outpatient consultations.

RESULTS:

Satisfaction reported was greater with transdermal than oral rivastigmine: mean ± SD of the total SATMED-Q score, 72.5 ± 14.1 vs. 65.2 ± 12.5, p < 0.001. The proportion of adherent patients was greater with transdermal than with oral rivastigmine (65.0 vs. 41.4%, p < 0.001). Satisfaction, in turn, was significantly greater in adherent cases than in nonadherent cases.

CONCLUSIONS:

Facilitating the administration of anti-dementia drugs would improve adherence.

PMID:
23306147
DOI:
10.1159/000345989
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center